HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Angiotensin Receptor Antagonists

Subscribe to New Research on Angiotensin Receptor Antagonists

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.

Also Known As:

Angiotensin II Receptor Antagonists; Angiotensin II Receptor Blockers; Angiotensin Receptor Blockers; Antagonists, Angiotensin Receptor; Receptor Antagonists, Angiotensin; Receptor Blockers, Angiotensin

Networked: 2402 relevant articles (217 outcomes, 427 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 56
  - Molecular Mechanisms of Pharmacological Action: 7
    - Angiotensin Receptor Antagonists: 2402
      - Angiotensin II Type 1 Receptor Blockers: 195
      - Angiotensin II Type 2 Receptor Blockers: 1

Experts

1.	Aronow, Wilbert S: 16 articles (01/2015 - 11/2003)
2.	Volpe, Massimo: 15 articles (01/2014 - 12/2005)
3.	Remuzzi, Giuseppe: 14 articles (03/2015 - 03/2003)
4.	Bakris, George L: 14 articles (04/2012 - 06/2002)
5.	Fonarow, Gregg C: 13 articles (03/2014 - 05/2006)
6.	Sica, Domenic A: 13 articles (04/2010 - 06/2002)
7.	Yusuf, Salim: 12 articles (10/2015 - 06/2005)
8.	Schiffrin, Ernesto L: 12 articles (04/2013 - 05/2002)
9.	Weir, Matthew R: 11 articles (04/2015 - 06/2003)
10.	Verdecchia, Paolo: 11 articles (01/2014 - 04/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 04/01/2007 - "The combination of a low-dose diuretic with agents that block the effects of the renin-angiotensin system (RAS), such as angiotensin receptor blockers, has been found in numerous clinical trials to be highly effective for lowering blood pressure in patients with uncomplicated as well as high-risk hypertension, with a comparable favorable side effect profile compared with monotherapy. " 07/01/2001 - "Angiotensin receptor blockers have proven highly effective in the management of hypertension. " 01/01/2011 - "Angiotensin II receptor blockers are compounds with a good margin of safety widely used in the treatment of hypertension and their anti-inflammatory and vascular protective effects contribute to reduce renal and cardiovascular failure. " 09/01/2009 - "Angiotensin II receptor blockers have been shown to be effective in treating both hypertension and connected organ damages. " 05/01/2002 - "Angiotensin II receptor antagonists, being effective in lowering blood pressure and particularly well tolerated, may represent, in the future, the first-line drugs for treating hypertension in women."
2.	Heart Failure 11/30/1999 - "Exercise tolerance as a guide to therapeutic efficacy for heart failure : the potential for angiotensin receptor blockers." 08/01/2006 - "It is known that the angiotensin receptor blockers (ARBs) have organ protective effects in patients with heart failure or renal impairment. " 12/01/2006 - "The publication of trials of angiotensin receptor blockers (ARBs) in recent years has led to the need to update the European Society of Cardiology guidelines for the management of chronic heart failure. " 05/01/2013 - "In hospitalized older patients with heart failure and preserved ejection fraction not receiving angiotensin receptor blockers, discharge initiation of ACE inhibitor therapy was associated with a modest improvement in the composite end point of total mortality or heart failure hospitalization but had no association with individual end point components." 03/12/2001 - "The role of angiotensin receptor blockers in the management of chronic heart failure."
3.	Proteinuria 01/01/2006 - "These results indicate that the addition of HBO therapy to a conventional regime, angiotensin receptor blockers, has significant benefits in the management of proteinuria. " 07/01/2003 - "Angiotensin receptor antagonists are effective in reducing proteinuria by an action independent of blood pressure. " 03/01/2014 - "Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials." 01/01/2009 - "Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study." 10/01/2003 - "No studies to date have examined the reduction of proteinuria achieved by angiotensin receptor blockers. "
4.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2012 - "The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). " 07/01/2012 - "This study aimed to investigate the beneficial effects of angiotensin receptor blockers (ARBs) on markers of endothelial function in patients with early stage of diabetic nephropathy (DN). " 03/01/2008 - "Clinical trials have found angiotensin receptor blockers (ARBs) to be more beneficial than traditional antihypertensive therapy in patients with type 2 diabetic nephropathy (DN). " 08/01/2005 - "Recent clinical trials have supported the use of angiotensin II receptor antagonists in the treatment of diabetic nephropathy, resulting in the approval of new therapeutic indications in the US and Europe. " 08/07/2004 - "Several studies have found that angiotensin-II receptor antagonists have a renoprotective effect in type 2 diabetics with diabetic nephropathy, independently of their antihypertensive effects. "
5.	Stroke (Strokes) 06/01/2007 - "Angiotensin receptor blockers (ARBs) exert a dual influence, which is important in their stroke protective effects. " 12/01/2009 - "Angiotensin receptor blockers were associated with a significant reduction in the risk of stroke than placebo with an OR of 0.91 (0.84 to 0.98). " 01/01/2013 - "We performed a systematic review of randomized controlled trials that investigated the effects of the angiotensin receptor blockers (ARBs) administered in the acute phase (≤72 hours) of stroke on death and dependency. " 09/01/2010 - "However, a lower incidence of AF in patients randomized to angiotensin receptor blockers may explain reductions in stroke risk in some trials." 09/01/2010 - "Angiotensin receptor blockers tended to reduce new-onset AF (OR 0.85; 95% CI 0.71 to 1.01; P=0.067; 4 trials; 47 482 patients) with significant reductions in 2 individual trials but had no consistent reduction on variability in BP. Effects of randomized treatment on variability in BP are unrelated to risk of new-onset AF, suggesting that other mechanisms account for the link between variability and stroke risk. "

Related Drugs and Biologics

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	Angiotensin II
4.	Diuretics
5.	Antihypertensive Agents (Antihypertensives)
6.	Calcium
7.	Losartan (Cozaar)
8.	Calcium Channel Blockers (Blockers, Calcium Channel)
9.	Amlodipine (Norvasc)
10.	Renin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Electric Countershock (Cardioversion)
3.	Transplantation (Transplant Recipients)
4.	Radiotherapy
5.	Renal Dialysis (Hemodialysis)